格列美脲与格列齐特治疗糖尿病的临床价值对比(1)
[摘要] 目的 对比分析在糖尿病治疗中格列美脲与格列齐特的临床应用价值。方法 随机选择84例从2017年6月—2019年6月于该院接受诊治并确诊为糖尿病的患者纳为实验对象，并将其按临床治疗方案的不同分别分为相对应的两组(一般组与观察组)进行差异性治疗，每组42例。给予一般组患者格列齐特进行常规治疗，对观察组患者则采用格列美脲进行治疗，而后就两组患者治疗效果、不良反应发生率以及治疗前后的血糖水平变化情况进行对比分析。结果 实施不同治疗方案后，观察组患者的治疗总有效率95.24%高于一般组患者的78.57%，不良反应总发生率7.14%低于一般组患者的23.80%，且两者相关数据均差异有统计学意义(P<0.05)。此外，两者亦在治疗后的血糖水平指标相关数据中观察组低于一般组，差异有统计学意义(P<0.05)。结论 与格列齐特相比，采用格列美脲对糖尿病患者进行治疗，不仅能够快速降低其血糖水平，并且还可最小化不良反应发生率，取得较为理想的临床疗效，临床可依据患者的实际病情适当借鉴与推广。
[关键词] 格列美脲;格列齐特;糖尿病;不良反应发生率
[Abstract] Objective To compare and analyze the clinical application value of Glimepiride and Glimezide in the treatment of diabetes. Methods Randomly select 84 patients who were diagnosed and diagnosed with diabetes in the hospital from June 2017 to June 2019 as experimental subjects， and divided them into corresponding two groups according to different clinical treatment schemes (general Group and observation group) for differential treatment， 42 cases in each group. Glezide was given to the general group for routine treatment， and Glimepiride was used for the observation group. Then， the treatment effect， incidence of adverse reactions， and changes in blood glucose levels before and after treatment were compared and analyzed. Results After implementing different treatment schemes， the total effective rate of treatment in the observation group was 95.24% higher than that of the general group of 78.57%， and the total incidence of adverse reactions was 7.14% lower than that of the general group of 23.80%. The related data had statistical significant difference(P<0.05). In addition， there was a statistical difference between the two in the data related to blood glucose levels after treatment ，the observation group was lower than the general group(P<0.05). Conclusion Compared with gliclazide， the treatment of diabetic patients with glimepiride can not only reduce its blood glucose level quickly， but also minimize the incidence of adverse reactions， and achieve better clinical efficacy. The actual condition is appropriately used for reference and promotion.
[Key words] Glimepiride; Glimizide; Diabetes; Incidence of adverse reactions
從医学的角度来看，糖尿病属于一种以高血糖为特征且病程较为漫长的代谢性疾病[1]。WHO的临床相关调查资料显示，糖尿病的产生与患者自身的遗传因素以及日常所处环境因素有着千丝万缕的联系，病发时，糖尿病患者通常会出现多饮多食、机体肥胖、多尿以及消瘦疲乏等一系列临床表现。在糖尿病的发病早期阶段，几乎无任何明显症状或仅伴有口渴、轻度乏力等现象，极易被患者本身和临床所忽视，待到来院就诊时，大多数患者的病情已经步入中后期阶段，错过了最佳的治疗时机。部分糖尿病专家指出，虽然降低患者血糖水平是抑制其病情恶化的主要治疗机制，但在治疗过程中还必须注意避免患者出现低血糖。还有部分临床相关研究显示，目前，临床针对糖尿病患者的治疗仍以降血糖为主，而有相当一部分学者对于格列美脲与格列齐特的综合应用价值存在一定的争议。因此，为能够在不断降低糖尿病患者血糖水平的同时进一步提高临床治疗的安全可靠性，促使其早日回归健康生活，该文选取2017年6月—2019年6月收治的84例患者，深入探讨了分别采用格列美脲与格列齐特对糖尿病患者进行给药的治疗效果，现报道如下。, 百拇医药(于晓红)
[关键词] 格列美脲;格列齐特;糖尿病;不良反应发生率
[Abstract] Objective To compare and analyze the clinical application value of Glimepiride and Glimezide in the treatment of diabetes. Methods Randomly select 84 patients who were diagnosed and diagnosed with diabetes in the hospital from June 2017 to June 2019 as experimental subjects， and divided them into corresponding two groups according to different clinical treatment schemes (general Group and observation group) for differential treatment， 42 cases in each group. Glezide was given to the general group for routine treatment， and Glimepiride was used for the observation group. Then， the treatment effect， incidence of adverse reactions， and changes in blood glucose levels before and after treatment were compared and analyzed. Results After implementing different treatment schemes， the total effective rate of treatment in the observation group was 95.24% higher than that of the general group of 78.57%， and the total incidence of adverse reactions was 7.14% lower than that of the general group of 23.80%. The related data had statistical significant difference(P<0.05). In addition， there was a statistical difference between the two in the data related to blood glucose levels after treatment ，the observation group was lower than the general group(P<0.05). Conclusion Compared with gliclazide， the treatment of diabetic patients with glimepiride can not only reduce its blood glucose level quickly， but also minimize the incidence of adverse reactions， and achieve better clinical efficacy. The actual condition is appropriately used for reference and promotion.
[Key words] Glimepiride; Glimizide; Diabetes; Incidence of adverse reactions
從医学的角度来看，糖尿病属于一种以高血糖为特征且病程较为漫长的代谢性疾病[1]。WHO的临床相关调查资料显示，糖尿病的产生与患者自身的遗传因素以及日常所处环境因素有着千丝万缕的联系，病发时，糖尿病患者通常会出现多饮多食、机体肥胖、多尿以及消瘦疲乏等一系列临床表现。在糖尿病的发病早期阶段，几乎无任何明显症状或仅伴有口渴、轻度乏力等现象，极易被患者本身和临床所忽视，待到来院就诊时，大多数患者的病情已经步入中后期阶段，错过了最佳的治疗时机。部分糖尿病专家指出，虽然降低患者血糖水平是抑制其病情恶化的主要治疗机制，但在治疗过程中还必须注意避免患者出现低血糖。还有部分临床相关研究显示，目前，临床针对糖尿病患者的治疗仍以降血糖为主，而有相当一部分学者对于格列美脲与格列齐特的综合应用价值存在一定的争议。因此，为能够在不断降低糖尿病患者血糖水平的同时进一步提高临床治疗的安全可靠性，促使其早日回归健康生活，该文选取2017年6月—2019年6月收治的84例患者，深入探讨了分别采用格列美脲与格列齐特对糖尿病患者进行给药的治疗效果，现报道如下。, 百拇医药(于晓红)
参见：首页 > 医疗版 > 疾病专题 > 内分泌科 > 糖尿病